{"id":"W4412461070","doi":"10.1016/s2352-3026(25)00163-2","title":"Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"GlaxoSmithKline","keywords":"Daratumumab; Medicine; Bortezomib; Dexamethasone; Multiple myeloma; Internal medicine; Oncology; Open label; Refractory (planetary science); Surgery; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003023389,0.001485867,0.003598238,0.0003440457,0.0004251893,0.001426597,0.001180471,0.00208992,0.004454115],"category_scores_gemma":[0.003564195,0.000600413,0.004114219,0.0004864158,0.001304979,0.001374783,0.0006518799,0.003644847,0.0005577451],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001167713,"about_ca_system_score_gemma":0.0008778985,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00107725,"about_ca_topic_score_gemma":0.001889696,"domain_scores_codex":[0.9979789,0.00124367,0.0001823966,0.000279174,0.0001344925,0.0001815423],"domain_scores_gemma":[0.9973936,0.001046202,0.0008393446,0.0001402534,0.0001135192,0.0004670111],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9822193,0.001599065,0.001147988,0.001062162,0.003751113,0.00002116635,0.0000433345,0.0002139047,0.0005747377,0.00006589203,0.000409944,0.008891307],"study_design_scores_gemma":[0.9533098,0.03870253,0.004123962,0.0001195914,0.00252469,0.00003815473,0.00004513994,0.0002739306,0.0001833647,0.0001888313,0.0004647622,0.00002523257],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9738761,0.02143426,0.0003104043,0.0008212326,0.0005940865,0.0008967014,0.0009081612,0.00004389021,0.001115324],"genre_scores_gemma":[0.9905016,0.004599372,0.0007951259,0.0007612258,0.0004621689,0.001314548,0.0007478911,0.00001146965,0.0008065624],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004454115,"threshold_uncertainty_score":0.01598936,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04989390241174046,"score_gpt":0.3510920310800825,"score_spread":0.301198128668342,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}